Why the study?
Identifying and understanding biomarkers associated with cardiorenal syndrome is valuable for early detection and enabling intervention before significant organ dysfunction occurs.
Key points are not available for this paper at this time.
Design
Literature review
Emphasizes integrated cardiorenal monitoring with biomarkers; leaves open prospective trials to guide subtype-specific therapies.
Cardiorenal syndrome (CRS) is a condition characterized by the intricate two-way relationship between the heart and kidneys, which can lead to acute or chronic dysfunction in these organs. The interplay between cardiorenal connectors and both hemodynamic and non-hemodynamic factors is crucial to understanding this syndrome. The clinical importance of these interactions is evident in the changes observed in hemodynamic factors, neurohormonal markers, and inflammatory processes. Identifying and understanding biomarkers associated with CRS is valuable for early detection and enabling intervention before significant organ dysfunction occurs. This comprehensive review focuses on the clinical significance of biomarkers in the diagnosis, prognosis, and management of CRS. Finally, it highlights the necessity for further advancements in managing this condition.
No takes yet. Share an insight, caveat, or question.
Ajibowo et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: